 |
|
Experience with Amphotericin B for the Treatment of Systemic Mycoses
JOHN H. SEABURY, M.D.;
HARRY E. DASCOMB, M.D.
AMA Arch Intern Med. 1958;102(6):960-976.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Amphotericin B is an antibiotic produced by a species of Streptomyces. It appears to have no important antibacterial properties, but possesses highly significant activity against those yeast-like fungi which produce deep mycotic infection in man. Table 1 contains the in vitro sensitivities of the major producers of deep mycotic infection in man as determined by various investigators.1-3 Our own findings, on Sabouraud's dextrose agar at pH 7, are indicated in the Table.
Studies in experimental animals2,3 have indicated a good correlation between in vivo effectiveness and in vitro sensitivity to amphotericin B. Animal toxicity studies carried out by the Squibb Institute for Medical Research indicated that amphotericin B had a therapeutic index sufficient to justify clinical trial in human mycotic infections. Several reports 4-6 of its use in histoplasmosis and cryptococcosis have already appeared in the American literature.
Routes of Administration and Toxicity
The insolubility of crystalline or
. . . [Full Text PDF of this Article]
Author Affiliations
New Orleans
From the Department of Medicine of Louisiana State University Medical School and the Lung Station of Charity Hospital.
Footnotes
Submitted for publication May 27, 1958.
This work was supported by a grant from the Squibb Institute for Medical Research, New Brunswick, N. J.
Read before the Section on Internal Medicine at the 107th Annual Meeting of the American Medical Association, San Francisco, June 25, 1958.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
